Results: 68 of 207 patients (33%) in the MABp1 arm achieved the primary endpoint vs 19 of 102 (19%) in the placebo arm (p ¼ 0.0045). Pre-treatment IL-1Ra data were available in 204 of 207 MABp1-treated and 100 of 102 placebo-treated patients. There was no significant difference in median pre-treatment plasma levels of IL-1Ra between MABp1 and placebo groups (926 (IQR 111 to 2471) vs 972 (963 to 2078) pg/ml respectively, p ¼ 0.71). However, in the MABp1 group, patients who met the primary endpoint had significantly lower IL-1Ra levels compared to those who did not (843 (IQR 555 to 1165) vs 1035 (IQR 702 to 1602), p ¼ 0.0092) ( Table) ; IL-1Ra levels were not different by outcome status in the placebo-treated patients (p ¼ 0.55). A logistic regression model demonstrated an independent relationship between baseline IL-1Ra and benefit in the MABp1-treated patients (odds ratio for lower baseline IL-1Ra in patients who benefitted were 1.7 (95% CI 1.1 to 2.6, p ¼ 0.017 (MABp1 arm) vs 1.2 (95% CI 0.6 to 2.5, p ¼ 0.57 (placebo arm))). Conclusion: Patients with mCRC receiving the anti-IL-1a antibody MABp1 in a randomized Phase III study were significantly more likely to show symptom/lean mass benefit (the primary study outcome) than those receiving placebo. Further, patients with lower baseline IL-1Ra levels were significantly more likely to show benefit in the MABp1 arm but not in the placebo arm. These data provide evidence that MABp1 selectively targets IL-1a and this antagonism is related to the primary outcome achieved in the Phase III study. Introduction: Based on the results of randomized trials, bevacizumab (bev) is effective in 1st, 2nd lines of chemotherapy (CT) and beyond of progression for the entire patients (pts) population. At the same time there is no clear evidence for the effectiveness of bev in case of mKRAS pts, especially, in 2nd line of CT and beyond of progression. We have reviewed the effectiveness of different sequences of combination CT and bev in pts with mKRAS mCRC who received 2 lines of systemic therapy in routine clinical practice Methods: We have collected personal data of 479 pts from 17 clinics in 14 regions of Russia who began to receive 1st line at the quarter of 2013. The criteria for inclusion were the following: presence of mutations in KRAS gene, receiving at least two lines of CT for mCRC. Four groups of pts were formed depending on the combination of bev with CT in 2 lines: CT/CT, CTþbev/CT, CT/CTþbev; CTþbev/CTþbev. Overall survival (OS) was the primary endpoint. Statistical analysis was performed in IBM SPSS statistics v.20 software package Results: Only 97 pts (20%) meet inclusion criteria: CT/CT -46 (47%), CTþbev/CT -17 (18%), CT/CTþbev -21 (22%); CTþbev/CTþbev -13 pts (13%). Groups were comparable for the main prognostic factors such as number of organs with metastases, presence of adjuvant CT, localization of metastasis, sex, age, removal of the primary tumor. Median follow up was 27 months (6-67). Median OS in the CT/CT group was 22, CTþbev/CT -27, CT/CTþbev -21 and CTþbev/CTþbev -29 months. Results of pairwise comparisons of OS between groups are presented in the table. Conclusion: Our retrospective data showed that combination of CT with bev is effective only in the 1st line of treatment in pts with mKRAS mCRC.
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